Skip to main content

Table 2 Selected effectiveness parameters after three months, six months, 12 months, 18 months and 24 months

From: Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry

  Month 0 Month 3 Month 6 Month 12 Month 18 Month 24
Physician global assessment; median (IQR)
 persistent oligoJIA 40 (20; 63) 7 (2; 17) 3 (1; 13) 3(1;13.5) 3 (0; 13) 2 (0; 8)
 extended oligoJIA 45 (25; 65) 12 (4; 23) 8.5(2,5; 20,5) 3(1; 13.5) 3 (0; 13) 3 (0; 11)
 RF negative PA 54.5 (34; 79) 15 (5; 29) 9 (3; 20) 5 (1; 16) 3 (0; 10) 3 (0; 7)
parents/patient global assessment; median (IQR)
 persistent oligoJIA 35 (11; 55) 6 (2; 19) 4 (1; 13) 3 (0, 11) 2 (0, 9) 2 (0; 10)
 extended oligoJIA 36 (15; 55) 12(2; 29) 7 (2; 18) 5 (1,18) 3 (0; 17) 2 (0, 16)
 RF negative PA 44 (22; 63) 14 (4; 31) 8 (2; 22) 6 (1; 19) 3 (0; 19) 3 (0; 11)
CRP > 5; n (%)
 persistent oligoJIA 117 (33.7) 27 (13.6) 20 (11.1) 9 (5.4) 10 (6.6) 10 (8.1)
 extended oligoJIA 91 (45) 26 (20.6) 21 ((16.7) 17 (14.5) 12 (12.1) 11 (11.6)
 RF negative PA 217 (48.5) 53 (18.3) 53 (18.7) 44 (17.5) 22 (10.5) 18 (10.2)
  1. Data as observed. #Data are given as median and interquartile range (IQR) of patients on treatment as observed
  2. 100 mm scale was used to assess the patient’s and physician’s global assessment of disease activity (0 = best, 100 = worst) number of active joints (defined by the presence of swelling or, when absent, the limited range of motion accompanied by either pain or tenderness on motion)